PT-112 Receives Orphan Drug Status for Advanced Multiple Myeloma
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…
Myeloma
Most Canadians Wouldn’t Know Where to Turn If Diagnosed With Blood Cancer, Survey Finds
Some 68 percent of Canadians would feel helpless if they or someone close to them received a blood cancer diagnosis, found a recent poll commissioned…
Multiple Myeloma Patients in UK Gain Access to Ninlaro through Cancer Drugs Fund
Multiple myeloma patients in the United Kingdom can now potentially benefit from a new oral pill sold as Ninlaro…
Stem Cell Transplants Better Than New Therapies at Delaying Myeloma Progression, Analysis Finds
In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free…
Ethyol Pretreatment Reduces Gastrointestinal Side Effects of Bone Marrow Transplant in Myeloma Patients
Pretreating multiple myeloma patients with Ethyol (amifostine) prior to a stem cell transplant significantly reduces the transplant therapy’s gastrointestinal toxicity without compromising its efficacy, a…
Myeloma Research Foundation and Karyopharm Hoping Myeloma Therapy Progress Continues
The Multiple Myeloma Research Foundation and Karyopharm Therapeutics are hoping that 2018 will be as momentous a year as 2017 in their collaborative effort to develop…
Nanoparticle-targeted Phototherapy Tested in Mice; Might Be Multiple Myeloma Therapy Someday
Animal studies have shown that a new treatment strategy using phototherapy might be used to treat inaccessible cancers, including multiple myeloma. The therapy makes use…
Selinexor, Dexamethasone Combo Shows Promise in Heavily Treated Myeloma Patients
Multiple myeloma patients who received several prior lines of therapy showed promising response rates when treated with a combination of Karyopharm Therapeutics‘Â selinexor…
CRISPR Gene Editing Technique Featured in Upcoming Myeloma Immunotherapy Trial
A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the…
FDA to Give Priority Review to Darzalex Combinations for Multiple Myeloma
The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML